Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall safety and tolerability of eculizumab based on Adverse Events of Special Interest/Adverse Drug Reactions and Additional Adverse Events. | Through 26 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Assess eculizumab treatment affect based on change in laboratory parameters (platelets, hemoglobin, LDH and parameters associated with renal function and intravascular hemolysis) and reduction of thrombotic microangiopathy (TMA). | Through 26 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Patients who have participated or are currently participating in a controlled clinical trial of eculizumab
Not provided
Not provided
Not provided
Not provided
Male or female patients of any age who have been diagnosed with aHUS.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dunwoody | Georgia | United States | ||||
Not provided
Not provided
Not provided
Not provided
| Chicago |
| Illinois |
| United States |
| Portland | Maine | United States |
| Boston | Massachusetts | United States |
| Durham | North Carolina | United States |
| Cincinnati | Ohio | United States |
| Oklahoma City | Oklahoma | United States |
| Corpus Christi | Texas | United States |
| Salt Lake City | Utah | United States |
| Seattle | Washington | United States |
| Spokane | Washington | United States |
| Appleton | Wisconsin | United States |
| Graz | Austria |
| Innsbruck | Austria |
| Montreal | Quebec | Canada |
| Caen | France |
| Le Kremlin-Bicêtre | France |
| Paris | France |
| Berlin | Germany |
| Heidelberg | Germany |
| Amsterdam | Netherlands |
| Barcelona | Spain |
| Bern | Switzerland |
| ID | Term |
|---|---|
| D065766 | Atypical Hemolytic Uremic Syndrome |
| ID | Term |
|---|---|
| D006463 | Hemolytic-Uremic Syndrome |
| D014511 | Uremia |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D057049 | Thrombotic Microangiopathies |
| D013921 | Thrombocytopenia |
| D001791 | Blood Platelet Disorders |
| D000095542 | Cytopenia |
Not provided
Not provided